for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Anavex Life Sciences Announces Exceeding Of Enrollment Target For Anavex2-73 U.S. Phase 2 Rett Syndrome Clinical Trial

June 16 (Reuters) - Anavex Life Sciences Corp:

* ANAVEX LIFE SCIENCES ANNOUNCES EXCEEDING OF ENROLLMENT TARGET FOR THE ANAVEX®2-73 (BLARCAMESINE) U.S. PHASE 2 RETT SYNDROME CLINICAL TRIAL

* ANAVEX LIFE SCIENCES - EXPECTS TO ANNOUNCE TOPLINE RESULTS FROM STUDY IN 2H 2020 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up